Limantrafin

Limantrafin (CB-103) is a first-in-class, orally active protein-protein interaction (PPI) inhibitor of the NOTCH transcriptional activation complex. Limantrafin has anti-tumor activity[1][2][3][4].

Product Specifications

CAS Number

[218457-67-1]

Product Name Alternative

CB-103

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Notch

Type

Reference compound

Related Pathways

Neuronal Signaling; Stem Cell/Wnt

Applications

Neuroscience-Neuromodulation

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/limantrafin.html

Purity

99.97

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

NC1=CC=C(OC2=CC=C(C(C)(C)C)C=C2)N=C1

Molecular Formula

C15H18N2O

Molecular Weight

242.32

Precautions

H302, H315, H319, H335

References & Citations

[1]Freddy Radtke, et al. Inhibitors of notch signalling pathway and use thereof in treatment of cancers. US9296682B2.|[2]R.Lehal, et al. Development of a novel first-in-class oral inhibitor of the NOTCH pathway.|[3]Rajwinder Lehal, et al. Non clinical pharmacology, pharmacokinetics and safety profiling of CB-103: A novel first-in-class small molecule inhibitor of the NOTCH pathway.|[4]Jose Manuel Perez Garcia, et al. First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.